- CALM Phase 3 program consists of two pivotal trials (CALM-1 and CALM-2), with primary efficacy endpoint of 24-hour cough frequency measured at 12- and 24-weeks, respectively - - The Company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback